About us

SAB

Dr. Scott A. Biller


Over 35 years of experience in biopharma discovery and development.

Retired as CSO of Agios Pharmaceuticals at the end of 2019, a position he held for over 9 years. At Agios, Dr. Biller led efforts to discover two approved medicines, TIBSOVO® and IDHIFA® for AML harboring IDH1 and IDH2 mutations, respectively, a third, mitapivat (for pyruvate kinase deficiency) that recently completed two positive Phase 3 trials and a fourth, vorasidenib (for IDH-mutated low-fgrade glioma) which is currently in Phase 3.

Prior to Agios, Dr. Biller held senior R&D leadership roles at Novartis and BMS.

B.S. in chemistry from MIT, Ph.D. in organic chemistry from Caltech, NIH Postdoctoral Fellowship at Columbia University.

Tel:(+86) 021-68912098

E-Mail:Public@abbisko.com Bd@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1